
Engineered endolysin proteins neutralizing antibiotic-resistant meningitis bacteria in the brain.
Image Credit: Scientific Frontline / stock image, AI generated
Scientific Frontline: Extended "At a Glance" Summary: Engineered Dual-Action Antibacterial Proteins
The Core Concept: Researchers have engineered a chimeric antibacterial protein that simultaneously eliminates antibiotic-resistant bacteria and neutralizes the destructive toxins they release.
Key Distinction/Mechanism: Unlike traditional antibiotics that often struggle to cross the blood-brain barrier, this engineered protein utilizes a bacteriophage-derived endolysin (Cpl-1) to destroy the bacteria while an attached peptide binds and neutralizes pneumolysin, the major toxin responsible for inflammation and neuronal damage in Streptococcus pneumoniae infections.
Major Frameworks/Components:
- Chimeric protein engineering for dual-action pathogen lysis and toxin neutralization.
- Utilization of bacteriophage endolysins to bypass traditional antibiotic resistance mechanisms.
- Targeted reduction of neuroinflammation and neuronal injury in the central nervous system.
- Blood-brain barrier permeability in neuropharmacological drug design.
Branches of Science: Molecular Medicine, Bacteriology, Neuropharmacology, Neuroimmunology, and Protein Engineering.
Future Application: This dual-action therapeutic model will undergo further optimization and translational testing for clinical use against resistant bacterial meningitis, with potential adaptation for other severe central nervous system and bloodstream infections like sepsis.
Why It Matters: Bacterial meningitis is a life-threatening medical emergency where standard antibiotics frequently fail due to antimicrobial resistance or an inability to penetrate the brain. By neutralizing harmful toxins alongside clearing the infection, this approach prevents severe neurological damage and significantly improves the chances of survival without lifelong complications.
Researchers at Karolinska Institutet have developed an engineered antibacterial protein that can kill antibiotic-resistant bacteria while also neutralizing toxins released by the bacteria. In a new study published in Molecular Medicine, the approach reduced harmful inflammation and neuronal damage in experimental models of bacterial meningitis.
Bacterial meningitis is a medical emergency that can lead to death or lifelong neurological complications. Treatment can be particularly challenging when the infection is caused by antibiotic-resistant bacteria. Traditional antibiotics often fail to cross the blood-brain barrier, a semipermeable membrane that protects the brain from circulating pathogens but inherently obstructs therapeutic drug delivery.
The researchers therefore investigated a different approach based on an endolysin, a protein enzyme derived from bacteriophages, viruses that infect bacteria. They engineered the naturally occurring endolysin Cpl-1 by attaching a peptide that targets pneumolysin, a virulent toxin released by Streptococcus pneumoniae—the leading global pathogen responsible for bacterial meningitis.
Dual-Action Therapeutic Mechanism
The resulting chimeric protein was designed with a dual-action mechanism: to lyse antibiotic-resistant bacterial strains and neutralize the specific toxins driving neuroinflammation and neuronal injury. It was tested using biochemical and microbiological methods, cell-based experiments, and a mouse model of meningitis.
“With this approach, we wanted to address two important causes of damage at the same time: the bacterial infection itself and the harmful effects of the toxins released by the bacteria,” says corresponding author Federico Iovino, associate professor at the Department of Neuroscience.
In in vivo murine models infected with penicillin-resistant S. pneumoniae, the engineered endolysin successfully eradicated the bacteria from both the bloodstream and brain tissue while significantly attenuating toxin-induced neuroinflammation and neuronal damage.
Future Translational Research
The results provide proof of concept for the approach, but it is not yet a treatment for patients. The researchers now plan to investigate delivery, dosage, and pharmacological properties and to test the method in models that more closely resemble the clinical situation.
Researchers are also investigating whether this dual-targeting mechanism can be adapted for other multidrug-resistant pathogens responsible for severe central nervous system infections and sepsis.
“The next step is to optimize the treatment and test it in increasingly translational models of meningitis before it can move toward clinical development,” says Federico Iovino.
Funding: The study was supported by the Swedish Research Council, Torsten Söderberg Foundation, Novo Nordisk Foundation, Karolinska Institutet, StratNeuro, and H.K.H. Crown Princess Lovisa's Association for Child Care. The biochemical characterization was carried out in collaboration with the laboratory of Daniel C. Nelson at the Institute for Bioscience and Biotechnology Research, University of Maryland, USA.
Published in journal: Molecular Medicine
Authors: Niels Vander Elst, Lotte Merlijn, Kristine Farmen, Valentina Mocci, Clara Caceffo, Daniel Kemboi, Adit B. Alreja, Daniel C. Nelson, and Federico Iovino
Source/Credit: Karolinska Institutet
Edited by: Scientific Frontline
Reference Number: med111826_01